Tysabri savings card: as little as $0 an infusion with commercial insurance

Tysabri is given by a doctor or nurse and billed by the clinic, not a pharmacy. Your care team and your insurance decide which product you get, so ask them what you’d pay.

How to pay the least

Given by your care team

Billed by the clinic

Tysabri is given by a doctor or nurse, not picked up at a pharmacy.

Ask your care team or your plan what you’d pay before your visit.

Compare every option

Brand nameTysabri

Authorized genericnatalizumab

Regular genericnatalizumab

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldAsk the pharmacy

Same as Tysabri?

The original

–

Brand nameThe maker’s card

TYSABRI Copay Program (Biogen Copay Program)

Savings card from Biogen

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $0 an infusion

Or call 1-800-456-2255.

In the maker’s words

“Eligible commercially insured patients may lower their out-of-pocket costs to as low as $0.”

From the maker’s offer on biogencopayprogram.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Authorized genericNot sold

There isn’t one. An authorized generic is Tysabri itself, from the same company, sold without the brand name, and usually for less. For now Tysabri is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

Tysabri is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

TYSABRI is an integrin receptor antagonist indicated for treatment of:

Multiple Sclerosis (MS)

TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk.

Crohn's Disease (CD)

TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.

Important Limitations:

In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α.

Source: the FDA label for Tysabri (Biogen Inc.), October 9, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to the clinic’s billing office.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/tysabri/